Cyclic, proteasome-mediated turnover of unliganded and liganded ERalpha on responsive promoters is an integral feature of estrogen signaling.
暂无分享,去创建一个
J. Ellenberg | F. Gannon | R. Métivier | J. Beaudouin | G. Reid | M. Hübner | H. Brand | S. Denger | Dominique Manu | Michaela Hübner
[1] R. Russell,et al. A dynamic structural model for estrogen receptor-alpha activation by ligands, emphasizing the role of interactions between distant A and E domains. , 2002, Molecular cell.
[2] T. Kodadek,et al. Physical association of the APIS complex and general transcription factors. , 2002, Biochemical and biophysical research communications.
[3] H. Hurst,et al. Targeting of SWI/SNF chromatin remodelling complexes to estrogen‐responsive genes , 2002, The EMBO journal.
[4] K. Yamamoto,et al. Disassembly of Transcriptional Regulatory Complexes by Molecular Chaperones , 2002, Science.
[5] D. DeFranco,et al. Proteasomal Inhibition Enhances Glucocorticoid Receptor Transactivation and Alters Its Subnuclear Trafficking , 2002, Molecular and Cellular Biology.
[6] G. Hager,et al. ATP-Dependent Mobilization of the Glucocorticoid Receptor during Chromatin Remodeling , 2002, Molecular and Cellular Biology.
[7] F. Gannon,et al. Human estrogen receptor-α: regulation by synthesis, modification and degradation , 2002, Cellular and Molecular Life Sciences CMLS.
[8] L. Freedman,et al. Reciprocal Recruitment of DRIP/Mediator and p160 Coactivator Complexes in Vivo by Estrogen Receptor* , 2002, The Journal of Biological Chemistry.
[9] Thomas Kodadek,et al. Recruitment of a 19S Proteasome Subcomplex to an Activated Promoter , 2002, Science.
[10] J. Qin,et al. Deubiquitination of p53 by HAUSP is an important pathway for p53 stabilization , 2002, Nature.
[11] E. Alarid,et al. Ligand-specific regulation of proteasome-mediated proteolysis of estrogen receptor-alpha. , 2002, American journal of physiology. Endocrinology and metabolism.
[12] S. Saccani,et al. Two Waves of Nuclear Factor κb Recruitment to Target Promoters , 2001, The Journal of experimental medicine.
[13] B. Katzenellenbogen,et al. Direct Acetylation of the Estrogen Receptor α Hinge Region by p300 Regulates Transactivation and Hormone Sensitivity* , 2001, The Journal of Biological Chemistry.
[14] J. Pietenpol,et al. Kinetics of p53 Binding to Promoter Sites In Vivo , 2001, Molecular and Cellular Biology.
[15] S. Nakashima,et al. MDM2 Enhances the Function of Estrogen Receptor α in Human Breast Cancer Cells , 2001 .
[16] Myles Brown,et al. Cofactor Dynamics and Sufficiency in Estrogen Receptor–Regulated Transcription , 2000, Cell.
[17] Heike Brand,et al. The 3'-Untranslated Region of the Human Estrogen Receptor α Gene Mediates Rapid Messenger Ribonucleic Acid Turnover. , 2000, Endocrinology.
[18] G. Géraud,et al. In mouse myoblasts nuclear prosomes are associated with the nuclear matrix and accumulate preferentially in the perinucleolar areas. , 2000, Journal of cell science.
[19] B. O’Malley,et al. The 26S Proteasome Is Required for Estrogen Receptor-α and Coactivator Turnover and for Efficient Estrogen Receptor-α Transactivation , 2000 .
[20] Carolyn L. Smith,et al. Subnuclear Trafficking of Estrogen Receptor-α and Steroid Receptor Coactivator-1 , 2000 .
[21] Tamoxifen-bound estrogen receptor (ER) strongly interacts with the nuclear matrix protein HET/SAF-B, a novel inhibitor of ER-mediated transactivation. , 2000, Molecular endocrinology.
[22] J. McNally,et al. The glucocorticoid receptor: rapid exchange with regulatory sites in living cells. , 2000, Science.
[23] B. O’Malley,et al. FRAP reveals that mobility of oestrogen receptor-α is ligand- and proteasome-dependent , 2000, Nature Cell Biology.
[24] E. Alarid,et al. Proteasome-mediated proteolysis of estrogen receptor: a novel component in autologous down-regulation. , 1999, Molecular endocrinology.
[25] M. O’Connor,et al. The Human Papillomavirus Type 16 E6 Oncoprotein Can Down-Regulate p53 Activity by Targeting the Transcriptional Coactivator CBP/p300 , 1999, Journal of Virology.
[26] K. Umesono,et al. A Unified Nomenclature System for the Nuclear Receptor Superfamily , 1999, Cell.
[27] N. McKenna,et al. Nuclear receptor coactivators: multiple enzymes, multiple complexes, multiple functionsProceedings of Xth International Congress on Hormonal Steroids, Quebec, Canada, 17–21 June 1998. , 1999, The Journal of Steroid Biochemistry and Molecular Biology.
[28] B. O’Malley,et al. Proteasome-dependent degradation of the human estrogen receptor. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[29] The Angelman Syndrome-Associated Protein, E6-AP, Is a Coactivator for the Nuclear Hormone Receptor Superfamily , 1999, Molecular and Cellular Biology.
[30] D. Livingston,et al. p300/MDM2 complexes participate in MDM2-mediated p53 degradation. , 1998, Molecular cell.
[31] Wolfgang Baumeister,et al. The Proteasome: Paradigm of a Self-Compartmentalizing Protease , 1998, Cell.
[32] H. Gronemeyer,et al. Reappraisal of the role of heat shock proteins as regulators of steroid receptor activity. , 1998, Critical reviews in biochemistry and molecular biology.
[33] S. Lindquist,et al. In vivo functions of the Saccharomyces cerevisiae Hsp90 chaperone. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[34] Zbigniew Dauter,et al. Molecular basis of agonism and antagonism in the oestrogen receptor , 1997, Nature.
[35] J. Trowsdale,et al. Dynamics of proteasome distribution in living cells , 1997, The EMBO journal.
[36] John H. White,et al. Selective Interaction of hsp90 with an Estrogen Receptor Ligand-binding Domain Containing a Point Mutation* , 1997, The Journal of Biological Chemistry.
[37] B. Henderson,et al. Estrogens and breast cancer. , 1996, Carcinogenesis.
[38] J. Polman,et al. ERβ: Identification and characterization of a novel human estrogen receptor , 1996 .
[39] H. Isom,et al. Nuclear scaffold-associated protease: In situ nuclear localization and effects of a protease inhibitor on growth and morphology of a ras-transformed hepatocyte cell line , 1995 .
[40] R. Thampan,et al. Ubiquitination of the rat uterine estrogen receptor: dependence on estradiol. , 1995, Biochemical and biophysical research communications.
[41] P. Webb,et al. Tamoxifen activation of the estrogen receptor/AP-1 pathway: potential origin for the cell-specific estrogen-like effects of antiestrogens. , 1995, Molecular endocrinology.
[42] D. Moore,et al. Interaction of thyroid-hormone receptor with a conserved transcriptional mediator , 1995, Nature.
[43] M. Parker,et al. Antiestrogen ICI 164,384 reduces cellular estrogen receptor content by increasing its turnover. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[44] J. Nickerson,et al. Core filaments of the nuclear matrix , 1990, The Journal of cell biology.
[45] P. Argos,et al. Human oestrogen receptor cDNA: sequence, expression and homology to v-erb-A , 1986, Nature.
[46] P. Chambon,et al. Cloning of cDNA sequences of hormone-regulated genes from the MCF-7 human breast cancer cell line. , 1982, Nucleic acids research.
[47] E. Jensen,et al. Estrogen-binding substances of target tissues. , 1969, Science.